Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 16 results.
User Information
Export Records
  1. 1.   HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells
  2. Maldarelli, F.; Wu, X.; Su, L.; Simonetti, F. R.; Shao, W.; Hill, S.; Spindler, J.; Ferris, A. L.; Mellors, J. W.; Kearney, M. F.; Coffin, J. M.; Hughes, S. H.
  3. Science. 2014, 11-Jul; 345(6193): 179-83.
  1. 2.   Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic
  2. Cotton, L. A.; Kuang, X. T.; Le, A. Q.; Carlson, J. M.; Chan, B.; Chopera, D. R.; Brumme, C. J.; Markle, T. J.; Martin, E.; Shahid, A.; Anmole, G.; Mwimanzi, P.; Nassab, P.; Penney, K. A.; Rahman, M. A.; Milloy, M. J.; Schechter, M. T.; Markowitz, M.; Carrington, M.; Walker, B. D.; Wagner, T.; Buchbinder, S.; Fuchs, J.; Koblin, B.; Mayer, K. H.; Harrigan, P. R.; Brockman, M. A.; Poon, A. F.; Brumme, Z. L.
  3. Plos Genetics. 2014, Apr; 10(4): e1004295.
  1. 3.   Identifying and characterizing recently transmitted viruses
  2. Keele, B. F.
  3. Current opinion in HIV and AIDS. 2010, Jul; 5(4): 327-34.
  1. 4.   Virus maturation as a new HIV-1 therapeutic target
  2. Adamson, C. S.; Salzwedel, K.; Freed, E. O.
  3. Expert opinion on therapeutic targets. 2009, Aug; 13(8): 895-908.
  1. 5.   Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets
  2. Adamson, C. S.; Freed, E. O.
  3. Molecular Interventions. 2009, Apr; 9(2): 70-4.
  1. 6.   Effects of human TRIM5 alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection
  2. Javanbakht, H.; An, P.; Gold, B.; Petersen, D. C.; O'Huigin, C.; Nelson, G. W.; O'Brien, S. J.; Kirk, G. D.; Detels, R.; Buchbinder, S.; Donfield, S.; Shulenin, S.; Song, B.; Perron, M. J.; Stremlau, M.; Sodroski, J.; Dean, M.; Winkler, C.
  3. Virology. 2006, Oct; 354(1): 15-27.
  1. 7.   Roles of substrate availability and infection of restina and activated CD4(+) T cells in transmission and acute simian immunodeficiency virus infection
  2. Zhang, Z. Q.; Wietgrefe, S. W.; Li, Q. S.; Shore, M. D.; Duan, L. J.; Reilly, C.; Lifson, J. D.; Haase, A. T.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2004 101(15): 5640-5645.
  1. 8.   HIV-1 induced in the setting of IL-2 therapy is transient and not derived from PBMC proviral reservoirs
  2. Imamichi, H.; Zhang, Y. M.; Kovacs, J.; Dewar, R.; Metcalf, J.; Vogel, S.; Salzman, N.; Lane, H. C.
  3. Conference on Retroviruses and Opportunistic Infections. 1999, 135 (abstract no. 358).
  1. 9.   Pathogenesis: disease mechanisms in humans and animal models the human genes that limit AIDS
  2. O'Brien, S.; Dean, M.; Carrington, M.; Winkler, C.; Smith, M.; Nelson, G.; Stephens, J. C.
  3. Conference on Retroviruses and Opportunistic Infections. 1999, 214 (abstract no. S14).
  1. 10.   The formation of a complex between CXCR4, CD4 and X4 HIV-1 envelope glycoprotein is inhibited in resistant to infection and fusion promonocytic U937 cells
  2. Xiao, X.; Norwood, D.; Feng, Y.; Moriuchi, H.; Moriuchi, M.; Earl, P.; Broder, C. C.; Fauci, A. S.; Dimitrov, D. S.
  3. Conference on Retroviruses and Opportunistic Infections. 1999, 166 (abstract no. 522).
  1. 11.   Differential effects of IL-4 on HIV-1 expression suggest a role in viral phenotypic switch and disease progression
  2. Pavlakis, G. N.; Valintin, A.; Lu, W.; Rosati, M.; Schneider, R.; Albert, J.; Karlsson, A.
  3. International Conference on AIDS. 1998, 12 273 (abstract no. 218/21174)).
  1. 12.   Dual effect of IL-4 on HIV-1 expression: implications for viral phenotypic switch and disease progression
  2. Pavlakis, G. N.; Valentin, A.; Lu, W.; Rosati, M.; Schneider, R.
  3. Conference on Retroviruses and Opportunistic Infections. 1998, 223 (abstract no. LB1).
  1. 13.   HIV replication persists in patients receiving HAART despite undetectable plasma virus
  2. Nata Rajan, V. N.; Chun, T. W.; O'Neill, D. P.; Metcalf, J. A.; Mican, J.; Engel, D.; Fauci, A. S.; Lane, H. C.; Kovacs, J. A.
  3. International Conference on AIDS. 1998, 12 341-2.
  1. 14.   Comparison of the Chiron ultrasensitive bDNA and original bDNA assays for the measurement of HIV RNA in plasma samples
  2. Highbarger, H.; Jiang, M.; Shaw, A.; Davis, I.; Lane, H. C.; Dewar, R.
  3. Conference on Retroviruses and Opportunistic Infections. 1997, 179 (abstract no. 618).
  1. 15.   Application of restriction enzyme analysis to screen drug-resistant mutations in HIV-protease and in proteolytic cleavage sites in the gag region
  2. Vasudevachari, M. B.; Imamichi, T.; Imamichi, H.; Zhang, Y. M.; Salzman, N. P.
  3. Conference on Retroviruses and Opportunistic Infections. 1997, 176 (abstract no. 606).
  1. 16.   Emergence of drug resistant HIV variants with mutations in the protease gene and gag cleavage sites during indinavir therapy
  2. Zhang, Y. M.; Imamichi, H.; Falloon, J.; Lane, H. C.; Vasudevachari, M. B.; Imamichi, T.; Salzman, N. P.
  3. Conference on Retroviruses and Opportunistic Infections. 1997, 175 (abstract no. 602).
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel